NCI Director Broder’s Year In Review: Avoid Politics, Stay Focused On Science
In Brief: Bruce Chabner, DC director, To Leave NCI Next Spring For Position At Mass General
“Our Job Is to Be The One Agency That Speaks To Cancer”
“The One Thing You Want From AN NCI Director: He Will Be Bound By The Facts”
NCABP “Anyone With Same Facts Would Have Come To Same Conclusion
Prevention Trial Could Stand On Its Own
Chabner : Opportunity To Set Own Agenda Reason For Leaving
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
